NASDAQ:ORPH - Orphazyme A/S Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $16.00
  • Forecasted Upside: 118.28 %
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$7.33
▼ -7.23 (-49.66%)
1 month | 3 months | 12 months
Get New Orphazyme A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ORPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ORPH

Average Price Target: $16.00
▲ +118.28% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Orphazyme A/S in the last 3 months. The average price target is $16.00, with a high forecast of $27.00 and a low forecast of $5.00. The average price target represents a 118.28% upside from the last price of $7.33.

Hold

The current consensus among 3 investment analysts is to hold stock in Orphazyme A/S.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/28/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
5/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/18/2021CowenDowngradeOutperform ➝ Market PerformLow
3/30/2021Bank of AmericaDowngradeNeutral ➝ Underperform$13.00 ➝ $5.00High
10/26/2020Bank of AmericaInitiated CoverageBuy$13.00High
10/26/2020GuggenheimInitiated CoverageBuy$27.00Medium
(Data available from 6/21/2016 forward)
Orphazyme A/S logo
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Read More

Today's Range

Now: $7.33
Low: $7.01
High: $9.35

50 Day Range

MA: $8.04
Low: $4.82
High: $21.00

52 Week Range

Now: $7.33
Low: $4.75
High: $77.77

Volume

96,340,896 shs

Average Volume

3,845,414 shs

Market Capitalization

$256.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Orphazyme A/S?

The following Wall Street research analysts have issued reports on Orphazyme A/S in the last twelve months: Bank of America Co., Cowen Inc, Guggenheim, and Zacks Investment Research.
View the latest analyst ratings for ORPH.

What is the current price target for Orphazyme A/S?

2 Wall Street analysts have set twelve-month price targets for Orphazyme A/S in the last year. Their average twelve-month price target is $16.00, suggesting a possible upside of 118.3%. Guggenheim has the highest price target set, predicting ORPH will reach $27.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $5.00 for Orphazyme A/S in the next year.
View the latest price targets for ORPH.

What is the current consensus analyst rating for Orphazyme A/S?

Orphazyme A/S currently has 1 sell rating, 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ORPH, but not buy more shares or sell existing shares.
View the latest ratings for ORPH.

What other companies compete with Orphazyme A/S?

How do I contact Orphazyme A/S's investor relations team?

Orphazyme A/S's physical mailing address is OLE MAALOES VEJ 3, COPENHAGEN N G7, DK-2200. The company's listed phone number is 45 39 17 82 72 and its investor relations email address is [email protected] The official website for Orphazyme A/S is www.orphazyme.com.